Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GENETRON HOLDINGS LIMITED

(GTH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genetron Added to FTSE Russell Global Equity Index Series

09/03/2021 | 11:08am EDT

BEIJING, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that Genetron will be added to the below FTSE Global Equity Index Series ("GEIS"), following FTSE's most recent quarterly review. These inclusions will become effective after the market close on Friday, September 17, 2021:

  • FTSE Global Small Cap Index – 富时全球小盘股指数
  • FTSE Global All-Cap Index (LMS) – 富时全市场指数(大中小型)
  • FTSE Global Total-Cap Index (LMSµ) – 富时完整全市场指数

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. FTSE GEIS provides a robust global equity index framework. The series includes over 16,000 large, mid, small, and micro-cap securities across 49 developed and emerging markets globally, with a wide range of modular indexes available to target specific markets and market segments. For more information, please refer to the Index page on FTSE's website at https://www.ftserussell.com/products/indices/geisac.

"We are very honored to be included in the FTSE indices, which are one of the most reputable index families in the world," commented Mr. Sizhen Wang, CEO and co-founder of Genetron Health. "This inclusion marks another significant capital market milestone since Genetron’s Nasdaq IPO debut in June 2020. Since our inception, we are dedicated in providing broader and better healthcare options globally. We are also pleased with our recent financial results, which continues to highlight our leading position in the precision oncology sector in China.”

About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
Hoki Luk
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 891-9255

Media Relations Contact
Yanrong Zhao
Genetron Health
Email: yanrong.zhao@genetronhealth.com


Primary Logo


© GlobeNewswire 2021
All news about GENETRON HOLDINGS LIMITED
10/22Health Care Stocks Relatively Flat Premarket Friday
MT
10/22GENETRON : Health Working With Jiangsu Fosun Pharmaceuticals to Commercialize Molecular Ca..
MT
10/22GENETRON : Health and Fosun Pharma Announce Exclusive Partnership to Commercialize Seq-MRD..
GL
09/27Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Sy..
GL
09/27Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Sy..
CI
09/16Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
GL
09/09GENETRON : September 2021 Corporate Presentation
PU
09/03GENETRON : to be Added to FTSE Global Equity Index Series Sept. 17
MT
09/03Genetron Added to FTSE Russell Global Equity Index Series
GL
09/03Genetron Holdings Limited Added to FTSE Russell Global Equity Index Series
CI
More news
Financials (USD)
Sales 2021 95,1 M - -
Net income 2021 -64,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -38,2x
Yield 2021 -
Capitalization 1 191 M 1 191 M -
Capi. / Sales 2021 12,5x
Capi. / Sales 2022 8,45x
Nbr of Employees 799
Free-Float 84,0%
Chart GENETRON HOLDINGS LIMITED
Duration : Period :
Genetron Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENETRON HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 13,40 $
Average target price 20,58 $
Spread / Average Target 53,6%
EPS Revisions
Managers and Directors
Si Zhen Wang Chief Executive Officer & Director
Ce Xu Chief Financial Officer
Wei-Wu He Chairman
Hai Yan Chief Scientific Officer & Director
Yu Chen Jiao Chief Technology Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
GENETRON HOLDINGS LIMITED-4.29%1 191
MODERNA, INC.212.57%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-2.12%31 638
CELLTRION, INC.-38.86%25 233